Table 2.
Association between history of HF/LVD at baseline and outcomes
| History of HF/LVD | No History of HF/LVD | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable Label | N events | CIF | N events | CIF | Unadjusted HR (95% CI) | Unadjusted p | Adjusted* HR (95% CI) | Adjusted* p |
| Primary outcome | 78 | 22.68 (17.79, 27.95) | 592 | 13.78 (12.67, 14.93) | 1.68 (1.32, 2.12) | <0.001 | 1.43 (1.12, 1.82) | 0.004 |
| CV death/MI | 67 | 19.74 (15.11, 24.82) | 523 | 12.26 (11.20, 13.37) | 1.61 (1.25, 2.08) | <0.001 | 1.37 (1.06, 1.78) | 0.016 |
| All-cause Death | 40 | 11.60 (8.05, 15.85) | 249 | 6.05 (5.25, 6.92) | 2.00 (1.43, 2.79) | <0.001 | 1.58 (1.13, 2.22) | 0.008 |
| CV Death | 33 | 9.51 (6.35, 13.44) | 170 | 4.15 (3.50, 4.88) | 2.42 (1.67, 3.52) | <0.001 | 1.89 (1.30, 2.77) | <0.001 |
| Primary Definition of MI | 44 | 13.25 (9.48, 17.65) | 399 | 9.26 (8.35, 10.23) | 1.38 (1.01, 1.89) | 0.041 | 1.22 (0.89, 1.67) | 0.223 |
| Unstable Angina | 3 | 0.78 (0.22, 2.14) | 45 | 1.05 (0.77, 1.42) | 0.84 (0.26, 2.70) | 0.771 | 0.83 (0.26, 2.69) | 0.758 |
| Hospitalization for Heart Failure | 17 | 4.46 (2.50, 7.25) | 59 | 1.30 (0.96, 1.73) | 3.61 (2.10, 6.20) | <0.001 | 2.73 (1.57, 4.75) | <0.001 |
| All-cause death or HF Hosp | 52 | 14.95 (10.91, 19.59) | 287 | 6.88 (6.04, 7.80) | 2.29 (1.70, 3.08) | <0.001 | 1.80 (1.33, 2.43) | <0.001 |
| HF death | 4 | 1.22 (0.31, 3.44) | 9 | 0.18 (0.07, 0.40) | 5.61 (1.72, 18.26) | 0.004 | 4.19 (1.25, 14.08) | 0.021 |
| NYHA Class II or greater† | 62 | 34.43 (27.10, 41.87) | 984 | 27.77 (26.18, 29.38) | 1.31 (1.01, 1.70) | 0.038 | 1.32 (1.02, 1.70) | 0.038 |
| Rose Dyspnea Scale 2 or more‡ | 91 | 40.63 (33.56, 47.58) | 1026 | 33.77 (31.91, 35.64) | 1.28 (1.03, 1.58) | 0.026 | 1.23 (0.99, 1.53) | 0.064 |
CV indicates cardiovascular; CIF, Cumulative incidence function; HF/LVD, heart failure/ left ventricular dysfunction; HR, hazard ratio; MI, myocardial infarction; NYHA, New York Heart Association
*
Adjusted for age (restricted cubic spline), sex, eGFR (restricted cubic spline), and diabetes.
†
NYHA Class II or greater outcome assessed at baseline and in each study visit is restricted to 4158 participants without NYHA Class II or greater at baseline.
‡
Rose Dyspnea Scale 2 or more outcome assessed at baseline and in each study visit is restricted to 3566 participants without Rose Dyspnea Scale 2 or more at baseline.